Aurora Cannabis: Consensus Estimates Point To Flat Quarterly Growth

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced that they will be reporting their fiscal third quarter financials after market close on March 13th. Analysts have a consensus C$12.58 12-month price target on the company, via a total of 13 analysts, with seven analysts having hold ratings, four analysts having sell ratings and two analysts having strong sell ratings. The street high comes from Bryan Garnier with a C$20 price target, and the lowest target comes from Stifel with a C$7.80 price target.

Twelve analysts have revenue estimates for the third quarter. The mean between all 12 is C$68.94 million; this number has been revised downwards from C$75.24 million at the start of the year. Piper Sandler currently has the highest revenue estimate with C$74.50 million, while the lowest comes from Stifel with a C$60 million estimate.

Only five analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 43.90%, with this number being revised downwards from 47.55% at the start of the year. Street high goes to Cantor Fitzgerald with a 53% estimate and the lowest sits at 31.50%

Onto EBITDA estimates, there are currently 10 analysts who have third quarter EBITDA estimates. The mean is currently (C$10.30) million, with this number being down from C$1.76 million at the start of the year. Street high goes to MKM Partners with a $0 million EBITDA estimate and the lowest being from Needham & Co with a (C$13.61) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Red Cloud Fall Mining Showcase 2026 | Day 1

Can an Old Irish Mine Recover the Silver It Left Behind? | Julian Vickers – Northmin Corporation

Is Gold at $4,000 a Buy Zone or a Breakdown? | David Morgan

Recommended

First Majestic Lifts Q3 Revenue 38% to US$394.1 Million on Higher Silver Prices

Meghan Markle’s Half-Brother Submitted Evidence Against Their Father, But Now Faces Philippine Police Scrutiny

Related News

Ascot Resources Sees BMO Lower Target To $1.25 Following Construction Delays

On June 23rd, Ascot Resources (TSX: AOT) provided investors with a series of updates. In...

Sunday, June 26, 2022, 11:07:00 AM

Trulieve: Canaccord Reiterates $97 Price Target Following First Quarter Results

Trulieve Cannabis (CSE: TRUL) reported its first-quarter financial results on May 13th, beating the analyst...

Sunday, May 16, 2021, 03:27:00 PM

Haywood Cuts Cresco Labs Price Target To $15.50 On Poor Earnings

At the tail end of March, Cresco Labs (CSE: CL) announced its fourth-quarter financial results,...

Sunday, April 3, 2022, 03:09:00 PM

Vireo Health: Canaccord Reiterates After Q4 Results

Last week, Vireo Health (CSE: VREO) released their fourth quarter and year-end 2020 financial results....

Monday, March 29, 2021, 04:03:00 PM

Tilray: Canaccord Cuts Price Target To $12 After Q1 Results

On October 7, Tilray Inc (TSX: TLRY) reported their first quarter financial results for the...

Tuesday, October 12, 2021, 10:17:00 AM